Voyager Acquisition shareholders approve Veraxa Biotech deal; 99.67% of Class A shares redeemed

Voyager Acquisition Corp./Cayman Islands

Shareholders approved business combination with Veraxa Biotech AG at March 12, 2026 meeting.
25,217,315 Class A shares redeemed (~99.67%), leaving ~$885,556 in trust account.
After closing, combined company to trade on Nasdaq as VRXA.
Remaining 82,685 Class A shares will convert into Veraxa Biotech Holding AG shares.
Closing subject to Nasdaq listing approvals and other customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.